Brief: Dermapharm Q2 EBITDA Up 3.7% In Q2 Versus Prior-Year Quarter
Aug 26 (Reuters) - DERMAPHARM HOLDING SE DMPG.DE: CONFIRMS STABLE BUSINESS DEVELOPMENT IN H1 2025 CONFIRMS OUTLOOK FOR 2025 OVERALL EBITDA UP 3.7% IN Q2 2025 VERSUS PRIOR-YEAR QUARTER Source text: ID:nEQ4RDzsZa Further company coverage: DMPG.DE (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit